TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: LF/HF ratio during sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Willingness to accept randomization
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Drop out of randomized trial if dissatisfied
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Strong treatment preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preparation for Decision Making Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Regret
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time Until Deterioration of Global Health (TUDD)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of C trachomatis infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Test sensitivity for ligase chain reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Test specificity for ligase chain reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: shoulder flexion and elbow extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of headache
Endpoint domain: Adverse events/effects
Primary endpoint: Moderate or severe pain experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of morphine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Decrease in VAS (Visual Analog Scale) pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in food intake (kilocalories per day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Th1/Th2 chemokine receptor ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: antibiotic charges
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: plantar deep temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of image guided biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: repeat biopsy rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to weight monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HF-related rehospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Increase in virus-specific CD4 memory T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: total wrinkle number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean number of wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: full neurological recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Freedom from treatment failure
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of left-to-right shunting at the level of the ductus arteriosus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Optimal placement of UVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: peak glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total glucose area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incremental clinical benefit from niacin therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CES-D total depressive score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 24-hour excretions of cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incidence of inpatient treatment
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: costs of inpatient treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Uterine bleeding patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mean uterine size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mean leiomyoma size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Pain control measured by VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative dose of intravenous morphine for supplemental analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pathological responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in micturitions per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in UUI episodes per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in mean voided volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgical failure
Endpoint domain: Mortality/survival
Primary endpoint: median recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Pain intensity at chest tube removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensation of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distress of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean score of processed volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to stand (mean FIM score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of anterior chamber cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of ocular pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28-day risk of treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary success rate
Endpoint domain: Mortality/survival
Primary endpoint: Mean MVA (Mitral Valve Area)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean TMG (Transmitral Gradient)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PICC failure incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged elimination phase of vatreptacog alfa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: IIEF EF improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean success rates for vaginal penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of claudication
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of PAOs providing information on clinical trials
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of PAOs mentioning expanded access (EA)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of PAOs providing resources for FDA's EA program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: enamel permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death/MI/TLR
Endpoint domain: Mortality/survival
Primary endpoint: major bleeding/vascular complications
Endpoint domain: Adverse events/effects
Primary endpoint: peak torque of maximal twitch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: time to reach peak torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean fiber coefficient of variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in midbrain rCBF after ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of VAS pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients regaining a spontaneous circulation (ROSC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital discharge rate
Endpoint domain: Mortality/survival
Primary endpoint: Mean carbon dioxide content during resuscitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for peripheral vascular access
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Catheter-related sepsis rates
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative discomfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: infections and severe complications
Endpoint domain: Adverse events/effects
Primary endpoint: 36-month MDI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of ziprasidone versus placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extrinsic tooth stain area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extrinsic tooth stain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-1beta and IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: subfertility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with ATDM calls
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in percentages of calories from fat and saturated fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increases in moderate to vigorous activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain and discomfort scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children with shigellacidal antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportions of circulating CD20+ and CD20+CD38+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Central Subfield Thickness (CST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discharge outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum uric acid (UA) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in acute headache medication use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean duration of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days without use of beta-agonists
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days without episodes of asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Increase of serum albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: humidification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mucus production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BAI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: panic-free status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating concentrations of total cysteine, glutathione and homocysteine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Annual rate of all ischemic events and death from any cause
Endpoint domain: Mortality/survival
Primary endpoint: Annual rates for vascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: CoQ10 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low CoQ10 levels (<.5 μg/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in surgical conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adverse events during surgical procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Severe asthma exacerbations prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: task completion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to complete tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dropout rates
Endpoint domain: Mortality/survival
Primary endpoint: Postoperative haze
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shuttle-walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of excessive criers
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ΔE values (color change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PI of G3 after 15 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of IL‐1β after 15 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decreased postprandial rates of normogastria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Absent postprandial increase of power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: enamel wear reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of delayed cerebral ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: poor functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Survival after treatment
Endpoint domain: Mortality/survival
Primary endpoint: Ovulation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cycle length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total behavioral score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative results of the Dix-Hallpike maneuver for positional nystagmus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of intraventricular hemorrhages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anxiety rating decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average ED stay duration
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Anaesthetic success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of correct responses to the knowledge test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of low HDL-cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: malnutrition in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the concentration × time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half-life of 25OHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in LDL-C concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: realism of vascular access
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: guide-wire manipulation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: vessel catheterization
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: immunogenicity of the vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain relief in OA patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function improvement in OA patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular risk (myocardial infarctions)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean lowest FEV(1) recorded
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: peak erythema values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of patients with moderate-to-severe symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quality of life improvement (IBS-QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Satisfaction scores of patients, surgeon, and anesthesiologist
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of BIS < 60
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relationship status (separation/divorce rates)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: postoperation blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: homologous blood-transfusion requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: steroid-free status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of biopsy proven acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TVR rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in probable anxiety and depression diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients emesis free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombelastographic parameters (R, angle alpha, MA, lysis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FOG score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major LARS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of blood pressure variation during nighttime
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum Aldrete recovery score 5 min after the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cholesterol-HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: free 25(OH)D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24,25(OH)2D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30% improvement in RMDQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of cardiovascular death, MI, and stroke
Endpoint domain: Mortality/survival
Primary endpoint: Moderate or severe bleeding risk
Endpoint domain: Adverse events/effects
Primary endpoint: 1-year survival estimate
Endpoint domain: Mortality/survival
Primary endpoint: Faster heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lower RMSSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ADL scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: conversion to normoalbuminuria and decrease in UACR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: time to doubling of serum creatinine or ESRD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cmax of lenalidomide and Revlimid®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of lenalidomide and Revlimid®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes